SCHEDULE: Deep Track Capital Exits Regulus Therapeutics Stake
Investor Ownership Update
Deep Track Capital and its affiliates have fully divested their beneficial ownership in Regulus Therapeutics Inc., reporting 0% stake.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 1 to Schedule 13G for Regulus Therapeutics Inc.
- As of June 30, 2025, the reporting persons beneficially own 0% of Regulus Therapeutics Inc.'s Common Stock.
- This filing indicates a complete divestment of their previous holdings in the company.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
- The calculation of beneficial ownership is based on 69,234,089 common shares outstanding as of May 2, 2025, as reported in the issuer's Form 10-Q.
Sentiment
Score: 3
Explanation: The complete divestment of shares by an institutional investor is generally a negative signal, indicating a lack of confidence or a strategic shift away from the company.
Negatives
- Deep Track Capital and its affiliates have fully divested their beneficial ownership in Regulus Therapeutics Inc., indicating a complete exit from their investment.
Future Outlook
No forward-looking statements or guidance from the issuer are provided in this filing.
Industry Context
This filing reflects an investment fund's decision to exit a position in a biotechnology company. Such divestments can occur for various reasons, including portfolio rebalancing, changes in investment strategy, or concerns about the company's prospects or the broader biotech market.
Stakeholder Impact
- Shareholders: Existing shareholders might view the divestment by an institutional investor negatively, potentially leading to downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 2025-05-02 | Date of common stock outstanding calculation (69,234,089 shares) as per issuer's Form 10-Q. |
| 2025-06-30 | Date of event which requires filing, indicating 0% beneficial ownership. |
| 2025-08-14 | Date of Schedule 13G Amendment No. 1 filing. |
Recommendation
sellThe complete divestment of shares by Deep Track Capital, an institutional investor, signals a significant lack of confidence in Regulus Therapeutics Inc. from their perspective. While the reasons for divestment are not disclosed, a full exit by a fund typically suggests a negative outlook or a re-evaluation of the investment's viability, which could lead to downward pressure on the stock price. Investors should consider this significant institutional exit as a potential red flag.
Keywords
Regulus Therapeutics, Deep Track Capital, Schedule 13G, Beneficial Ownership, Divestment, Biotechnology, Investment Fund, Stock Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.